ABL Bio is closing in on another partnership with a global pharmaceutical company for its proprietary Grabody-B technology, a ...

Merck’s MRK stock has risen 32.3% in the past three months. The stock has also been trading above its 50-day and 200-day ...

Lilly has launched six early-stage clinical programs, and 34 discovery programs with a focus on incretins, amylins, and novel ...

AbCellera Biologics (NASDAQ:ABCL) used its presentation at the 2026 JPMorgan Healthcare Conference to outline its shift from ...

Drugmaker CEOs see sales online channels as a budding opportunity, while some biotech investors told BioPharma Dive to expect ...

Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with ...

The bispecific antibody—which targets the IL-23p19 and TL1A pathways—was licensed from China’s Qyuns Therapeutics. Since ...

Celltrion reaffirmed its commitment to expanding both its biosimilar and novel drug pipelines as the Korean biopharmaceutical ...

Celltrion outlines a blueprint for innovative drug development built on its antibody expertiseThe company highlights its ...

The presence of circulating tumor DNA (ctDNA) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer after they received neoadjuvant treatment and surgery predicted ...

Nvidia and Eli Lilly are teaming up on a $1 billion AI-powered lab to accelerate drug discovery, combining robotics, molecular modeling and automated research workflows.

Converge Bio, the AI platform for accelerated drug discovery and development, announced today $25 million in Series A funding, bringing its total raised to $30 million. The round was led by Bessemer ...